Artificial intelligence has emerged as a transformative force in the biotechnology sector, with profound implications for drug discovery and development. According to Leen Kawas, Managing General Partner at Propel Bio Partners, successfully navigating this technological revolution requires careful attention to ethical considerations that will shape the industry’s future. “AI enables us to bring a number…